Core Insights - The Ping An Medical Health Mixed Fund C (020137) has a latest net value of 2.9022 yuan, reflecting a growth of 1.74% [1] - The fund's performance over the past month shows a return of 1.41%, ranking 681 out of 709 in its category; over the past six months, it has achieved a return of 64.61%, ranking 3 out of 687; and since the beginning of the year, it has returned 87.46%, ranking 6 out of 685 [1] Fund Holdings - The top ten stock holdings of the Ping An Medical Health Mixed Fund C account for a total of 75.91%, with the largest positions being: - Genscript Biotech (10.55%) - Innovent Biologics (9.08%) - CanSino Biologics (8.97%) - BeiGene (7.58%) - Kelun-Biotech (7.54%) - EdiGene (7.49%) - Boli Tianheng (6.34%) - Aier Eye Hospital (6.25%) - Zai Lab (6.13%) - Ascletis Pharma (5.98%) [1] Fund Manager Profile - Zhou Sicong, the fund manager, holds a master's degree in finance from Renmin University of China and has previously worked as a fund manager at YinHua Fund Management Co., Ltd. and Changsheng Fund Management Co., Ltd. She joined Ping An Fund Management Co., Ltd. in May 2023 [2]

Core Insights - The latest net value of Ping An Medical Health Mixed C (020137) is 2.8526 yuan, reflecting a decrease of 2.24% [1] - The fund's performance over the past month shows a return of -1.46%, ranking 4561 out of 4702 in its category; over the last six months, it has achieved a return of 72.15%, ranking 38 out of 4537; and since the beginning of the year, it has returned 84.25%, ranking 33 out of 4493 [1] Fund Holdings - The top ten stock holdings of Ping An Medical Health Mixed C account for a total of 75.91%, with the largest positions being: - Genscript Biotech (10.55%) - Innovent Biologics (9.08%) - CanSino Biologics (8.97%) - BeiGene (7.58%) - Kelun-Biotech (7.54%) - Eucure Biopharma (7.49%) - Boli Tianheng (6.34%) - Aier Eye Hospital (6.25%) - Zai Lab (6.13%) - Ascletis Pharma (5.98%) [1] Fund Manager Profile - Zhou Sicong, the fund manager, holds a master's degree in finance from Renmin University of China and has previously worked as a fund manager at Yin Hua Fund Management Co., Ltd. and Changsheng Fund Management Co., Ltd. She joined Ping An Fund Management Co., Ltd. in May 2023 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Ping An Medical Health Mixed C fund, which has shown significant growth in recent months and year-to-date [1] - As of August 18, 2025, the latest net value of the fund is 2.9725 yuan, reflecting a growth of 1.24% [1] - The fund's one-month return is 2.68%, six-month return is 81.82%, and year-to-date return is 92.00%, with respective rankings of 1127 out of 1212, 8 out of 1181, and 9 out of 1179 [1] Group 2 - The top ten stock holdings of the Ping An Medical Health Mixed C fund account for a total of 75.91%, with the largest holding being Ginkgo BioWorks at 10.55% [1] - Other significant holdings include Innovent Biologics (9.08%), CanSino Biologics (8.97%), and BeiGene (7.58%) [1] - The fund was established on November 28, 2023, and as of June 30, 2025, it has a total scale of 1.216 billion yuan, managed by fund manager Zhou Sicong [1][2]

Group 1 - The core viewpoint of the articles highlights that over 90% of public FOFs achieved net value growth in Q2 2025, with a focus on diversified asset allocation and structural opportunities in the equity market [1][4]. - Different fund managers have varying investment strategies, with some emphasizing structural opportunities in new productivity sectors such as new consumption, new technology, and new manufacturing [2][4]. - Specific funds like Penghua Yixuan and Chuangjin Hexin have reported significant net value growth rates of 6.95% and 6.06% respectively, showcasing their unique asset allocation strategies [2][3]. Group 2 - Fund managers are increasingly focusing on high-dividend assets and technology sectors, with funds like Chuangjin Hexin adjusting their allocations to emphasize value stocks and technology growth [3][4]. - The outlook for the second half of 2025 suggests a potentially better performance in the stock market due to external factors such as the Federal Reserve's interest rate cuts and domestic inventory replenishment cycles [5]. - Managers express optimism about structural investment opportunities in the capital market, particularly in the context of a low-interest-rate environment and the potential for risk appetite recovery [4][5].

Group 1 - The majority of stock and mixed funds achieved positive returns, with 89.57% reporting gains, and 52 funds exceeding a 5% return [1][2] - The Shanghai Composite Index rose by 0.43% to close at 3399.77 points, while the Shenzhen Component Index increased by 0.65%, and the ChiNext Index rose by 1.07% [1] - The top-performing sectors included pharmaceuticals, agriculture, and textiles, with respective increases of 2.30%, 1.72%, and 1.61% [1] Group 2 - The average net value growth rate for stock and mixed funds on June 9 was 0.68%, with 52 funds achieving over 5% growth [1][2] - The leading fund in terms of net value growth was Red Soil Innovation Healthcare Stock, with a growth rate of 7.36% [2] - Among the funds with over 5% growth, 9 belonged to Ping An Fund, while Great Wall Fund and Penghua Fund had 8 and 6 funds respectively [1][2] Group 3 - The funds with the highest net value declines included Gold Stock ETF, which fell by 1.11%, followed by Ping An and Guotai ETFs with declines of 1.10% and 1.09% respectively [2][3] - The data indicates a significant focus on healthcare-related funds, with multiple funds from Ping An Fund showing strong performance [1][2] - The report highlights the volatility in the gold sector, as evidenced by the performance of various gold-related ETFs [2][3]

Group 1 - The core point of the news is the performance and holdings of the Ping An Medical Health Mixed C fund, which has shown significant growth in recent months and has a concentrated portfolio in the healthcare sector [1][3] - As of May 19, 2025, the latest net value of the fund is 2.0524 yuan, reflecting a growth of 1.97%. The fund's one-month return is 1.13%, three-month return is 27.69%, and year-to-date return is 30.00% [1] - The top ten stock holdings of the fund account for a total of 83.49%, with significant positions in companies such as Kangfang Biotech (9.32%), BeiGene (9.13%), and Zai Lab (8.87%) [1] Group 2 - The Ping An Medical Health Mixed C fund was established on November 28, 2023, and as of March 31, 2025, it has a total scale of 1.339 billion yuan [1] - The fund manager, Zhou Sicong, has a strong background in the investment industry, having previously worked at various fund management companies and managing multiple funds focused on healthcare and competitive advantages [2]

Core Insights - The latest net value of Ping An Medical Health Mixed C (020137) is 1.9567 yuan, reflecting a decline of 4.93% [1] - The fund's performance over the past month shows a return of -2.07%, ranking 3393 out of 3457 in its category; over the last three months, it has achieved a return of 25.32%, ranking 25 out of 3416; and since the beginning of the year, it has returned 26.39%, ranking 59 out of 3387 [1] Fund Holdings - The top ten stock holdings of Ping An Medical Health Mixed C account for a total of 83.49%, with the largest positions being: - Kangfang Biotech (9.32%) - BeiGene-U (9.13%) - Boli Tianheng (8.95%) - Zai Lab (8.87%) - Yunding Xinyao-B (8.79%) - Nuocheng Jianhua-U (8.47%) - Zexing Pharmaceutical-U (8.47%) - Ailisi (8.27%) - Kelun-Botai (7.31%) - Dize Pharmaceutical-U (5.91%) [1] Fund Manager Profile - Zhou Sicong, the fund manager of Ping An Medical Health Mixed C, has a master's degree and has held various positions in the investment management industry, including roles at Yin Hua Fund Management and Changsheng Fund Management. She joined Ping An Fund Management in May 2023 [2]

Group 1 - The core point of the article highlights the performance and holdings of the Ping An Medical Health Mixed C fund, which has a latest net value of 2.0423 yuan, down by 4.04% [1] - The fund has shown a monthly return of 13.52%, ranking 1343 out of 4649 in its category, a three-month return of 29.39%, ranking 27 out of 4597, and a year-to-date return of 31.91%, ranking 40 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 83.49%, with significant positions in companies such as Kangfang Biotech (9.32%), BeiGene-U (9.13%), and others [1] Group 2 - The Ping An Medical Health Mixed C fund was established on November 28, 2023, and as of March 31, 2025, it has a total scale of 1.339 billion yuan [1] - The fund manager, Zhou Sicong, has a background in finance with experience at various fund management companies, including roles as a research analyst and fund manager [2]

金融界2025年4月21日消息，平安医疗健康混合C(020137) 最新净值2.0478元，增长2.96%。该基金近1个 月收益率7.41%，同类排名69|4672；近3个月收益率32.95%，同类排名39|4599；今年来收益率32.27%， 同类排名45|4590。 公开资料显示，平安医疗健康混合C基金成立于2023年11月28日，截至2025年3月31日，平安医疗健康 混合C规模13.39亿元，基金经理为周思聪。 简历显示：周思聪女士:硕士。曾任银华基金管理有限公司研究员、研究部总监助理、基金经理助理,基 金经理。2018年10月加入长盛基金管理有限公司。曾任长盛医疗行业量化配置股票型证券投资基金基金 经理。曾任长盛养老健康产业灵活配置混合型证券投资基金基金经理、长盛竞争优势股票型证券投资基 金基金经理。2023年5月加入平安基金管理有限公司,现任平安医疗健康灵活配置混合型证券投资基金的 基金经理(2023-11-07至今)。2023年11月15日起担任平安核心优势混合型证券投资基金基金经理。 来源：金融界 平安医疗健康混合C股票持仓前十占比合计83.49%，分别为：康方生物（9.32%）、百济神州-U ...